

Annex: Antibigram based on 2021 data from the Central Health Laboratory

Percentages represent susceptibility rates

For in-patients

	Pen	Tetra	Oxa	Erythro	Vanco	Cipro	Genta	Amik	Pip-tazo	Mero	Ceftr	Colistin
<i>Escherichia coli</i>		51%				50%	76%	37%	97%	93%	31%	99%
<i>Klebsiella pneumoniae</i>		35%				47%	46%	32%	81%	61%	21%	95%
<i>Acinetobacter spp.</i>						51%	52%	58%	52%	51%	18%	97%
<i>Staphylococcus aureus</i>	5%	95%	56%	91%	100%	63%	91%					
<i>Salmonella spp.</i>						100%	100%				100%	

For outpatients and emergency departments

	Tetracycline	Co-trimoxazole	Oxacillin	Vancomycin	Co-amoxiclav	Ceftriaxone
<i>Escherichia coli</i>	60%	57%			44%	40%
<i>Klebsiella pneumoniae</i>	47%	52%			51%	19%
<i>Staphylococcus aureus</i>	100%	100%	54%	100%		

For patients in ICUs

	Co-trimoxazole	Cefotaxime	Co-amoxiclav	Ciprofloxacin	Gentamicin	Amikacin	Piperacillin-tazobactam	Meropenem	Colistin
<i>Escherichia coli</i>	39%	31%	28%	29%	71%	46%	89%	83%	100%
<i>Klebsiella pneumoniae</i>	19%	10%	12%	31%	33%	40%	39%	48%	89%
<i>Acinetobacter spp.</i>	28%	2%	3%	12%	17%	24%	13%	12%	98%